Published in Blood on March 14, 2007
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand. Blood (2008) 1.03
TRAF2 and TRAF3 independently mediate Ig class switching driven by CD40. Int Immunol (2009) 0.80
Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish. Immunogenetics (2010) 0.79
Suppression by Δ(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation. Toxicology (2013) 0.77
The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis. ScientificWorldJournal (2011) 0.75
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science (1995) 6.41
Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science (1995) 3.76
Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A (1997) 3.68
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem (2004) 3.35
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem (1994) 3.13
Two pathways to NF-kappaB. Mol Cell (2002) 3.12
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 2.90
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice. Nature (1996) 2.43
TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci U S A (1996) 2.31
TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity (2004) 2.17
B cell memory and the long-lived plasma cell. Curr Opin Immunol (1999) 2.03
A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett (1995) 1.97
BCL-6 expression during B-cell activation. Blood (1996) 1.95
TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A (2005) 1.87
CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry (1998) 1.77
The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity (2002) 1.68
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J Virol (1996) 1.67
CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem (1999) 1.64
In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B. Mol Cell Biol (1995) 1.64
Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci U S A (2000) 1.64
Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem (1997) 1.60
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol (2002) 1.59
Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity (1997) 1.54
TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol (2002) 1.50
CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem (1996) 1.44
Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem (2003) 1.32
Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep (2005) 1.30
Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev (2003) 1.19
Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun (1997) 1.03
Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol (2002) 1.00
Differential regulation of CD40-mediated TNF receptor-associated factor degradation in B lymphocytes. J Immunol (2005) 0.98
Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling. Biochem Biophys Res Commun (2000) 0.94
Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem (2005) 0.92
Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation. J Biol Chem (2004) 0.90
Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity (1999) 0.90
CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem (2003) 0.85
Characterization of a 23-kDa protein associated with CD40. Proc Natl Acad Sci U S A (1995) 0.83
All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med (2007) 5.96
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest (2002) 4.04
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol (2005) 3.95
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med (2009) 2.78
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 2.38
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 2.26
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol (2006) 2.03
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity (2002) 1.89
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest (2002) 1.67
Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med (2002) 1.63
Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity (2009) 1.62
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol (2002) 1.59
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood (2003) 1.57
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest (2003) 1.50
Strategies for selective priming of memory B cells. Immunol Lett (2007) 1.47
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. J Exp Med (2011) 1.41
The immortality of humoral immunity. Immunol Rev (2010) 1.33
The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood (2008) 1.29
Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med (2009) 1.25
Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J Immunol (2005) 1.22
CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation (2003) 1.19
A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A (2003) 1.16
Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol (2008) 1.14
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev (2003) 1.13
The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev Cell (2012) 1.13
Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol (2007) 1.11
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
Retinoic acid in the immune system. Ann N Y Acad Sci (2008) 1.09
VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res (2014) 1.09
Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens. J Immunol (2008) 1.08
Characterization of (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific germinal center B cells and antigen-binding B220- cells after primary NP challenge in mice. J Immunol (2006) 1.07
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med (2012) 1.06
Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. J Immunol (2006) 1.05
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol (2002) 1.04
The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2011) 1.03
Mir-155, a central modulator of T-cell responses. Eur J Immunol (2014) 1.02
Mast cells condition dendritic cells to mediate allograft tolerance. Immunity (2011) 1.02
Interleukin-9 as a T helper type 17 cytokine. Immunology (2010) 1.01
Latent herpes simplex virus infection of sensory neurons alters neuronal gene expression. J Virol (2003) 1.01
KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol (2011) 1.01
Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol (2002) 1.00
HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. Proc Natl Acad Sci U S A (2010) 0.98
The roles of mast cells in anticancer immunity. Cancer Immunol Immunother (2012) 0.98
Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood (2002) 0.97
Retinoic acid: a key player in immunity. Biofactors (2010) 0.95
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res (2007) 0.93
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine (2011) 0.91
Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum (2003) 0.90
Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine (2009) 0.90
Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol Immunother (2012) 0.88
Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation. J Immunol (2013) 0.88
The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. J Virol (2007) 0.88
Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J Virol (2012) 0.87
The CD154/CD40 interaction required for retrovirus-induced murine immunodeficiency syndrome is not mediated by upregulation of the CD80/CD86 costimulatory molecules. J Virol (2002) 0.87
Mast cell mediators in tolerance. Curr Opin Immunol (2010) 0.86
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood (2013) 0.85
CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem (2003) 0.85
Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun (2013) 0.85
Interleukin-9 and T cell subsets. Cell Cycle (2009) 0.83
CD40-associated TRAF 6 signaling is required for disease induction in a retrovirus-induced murine immunodeficiency. J Virol (2004) 0.83